ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,416.45
-0.09%
Dow Jones
39,872.99
0.17%
Gold vs US Dollar
2,421.745
-0.19%
Brent Oil
82.445
-1.30%
Bitcoin
70,268.06
-1.65%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Galapagos NV (GLPG)

  7. Galapagos NV (GLPG) News

Galapagos NV (GLPG)

Galapagos NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GLPG
DateTimeSourceHeadlineSymbolCompany
16/05/202421:28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
16/05/202421:01GlobeNewswire Inc.Galapagos creates new subscription right plansNASDAQ:GLPGGalapagos NV
16/05/202413:11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
15/05/202421:01GlobeNewswire Inc.Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.NASDAQ:GLPGGalapagos NV
02/05/202421:01GlobeNewswire Inc.Galapagos reports first quarter 2024 financial results  NASDAQ:GLPGGalapagos NV
30/04/202421:01GlobeNewswire Inc.Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024NASDAQ:GLPGGalapagos NV
04/04/202421:01GlobeNewswire Inc.Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024NASDAQ:GLPGGalapagos NV
28/03/202420:01GlobeNewswire Inc.Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ MeetingsNASDAQ:GLPGGalapagos NV
26/03/202420:01GlobeNewswire Inc.Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its BoardNASDAQ:GLPGGalapagos NV
23/02/202411:41Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
22/02/202421:01GlobeNewswire Inc.Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage PipelineNASDAQ:GLPGGalapagos NV
22/02/202421:01GlobeNewswire Inc.Galapagos announces full year 2023 results and outlook for 2024NASDAQ:GLPGGalapagos NV
16/02/202411:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
15/02/202421:01GlobeNewswire Inc.Galapagos presents at EBMT-EHA annual meeting 2024NASDAQ:GLPGGalapagos NV
14/02/202422:41Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GLPGGalapagos NV
31/01/202421:01GlobeNewswire Inc.Galapagos completes transaction to transfer Jyseleca® business to AlfasigmaNASDAQ:GLPGGalapagos NV
04/01/202421:44Dow Jones NewsGalapagos, Thermo Fisher to Collaborate on Expanding Manufacturing of Cancer DrugNASDAQ:GLPGGalapagos NV
04/01/202421:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
04/01/202421:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
04/01/202421:01GlobeNewswire Inc.Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.NASDAQ:GLPGGalapagos NV
03/01/202421:01GlobeNewswire Inc.Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncologyNASDAQ:GLPGGalapagos NV
03/01/202421:01PR Newswire (US)BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology TargetsNASDAQ:GLPGGalapagos NV
02/01/202406:00GlobeNewswire Inc.Galapagos signs agreement to transfer Jyseleca® business to AlfasigmaNASDAQ:GLPGGalapagos NV
21/12/202321:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
19/12/202321:01GlobeNewswire Inc.Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301NASDAQ:GLPGGalapagos NV
09/12/202317:00GlobeNewswire Inc.Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101NASDAQ:GLPGGalapagos NV
07/12/202321:01GlobeNewswire Inc.Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023NASDAQ:GLPGGalapagos NV
06/11/202312:45PR Newswire (US)Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-CareNASDAQ:GLPGGalapagos NV
03/11/202312:26Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLPGGalapagos NV
02/11/202320:01GlobeNewswire Inc.Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023NASDAQ:GLPGGalapagos NV
 Showing the most relevant articles for your search:NASDAQ:GLPG

Your Recent History

LSE
BP.
Bp
LSE
SCLP
Scancell
LSE
TERN
Tern
LSE
POS
Plexus
LSE
VAST
Vast Resources
LSE
VAL
Valirx
LSE
YU.
Yu
LSE
GKP
Gulf Keystone Petroleum
LSE
POLX
Polarean Imaging
LSE
PHE
Powerhouse Energy
LSE
SOLG
Solgold
LSE
THG
Thg
LSE
SYME
Supply@me Capital
LSE
MIN
Minoan
LSE
TEK
Tekcapital
LSE
KEFI
Kefi Gold And Copper
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved